5 O
WARNINGS O
AND O
PRECAUTIONS O
EXCERPT O
: O
* O
Coagulopathy O
: O
May O
result O
in O
bleeding O
, O
death O
. O

Monitor O
anticoagulant O
response O
( O
e.g. O
, O
INR O
) O
and O
adjust O
anticoagulant O
dose O
accordingly O
. O

( O
5.1 O
) O
* O
Diarrhea O
: O
May O
be O
severe O
. O

Interrupt O
XELODA O
treatment O
immediately O
until O
diarrhea O
resolves O
or O
decreases O
to O
grade O
1 O
. O

Recommend O
standard O
antidiarrheal O
treatments O
. O

( O
5.2 O
) O
* O
Cardiotoxicity O
: O
Common O
in O
patients O
with O
a O
prior O
history O
of O
coronary O
artery O
disease O
. O

( O
5.3 O
) O
* O
Increased O
Risk O
of O
Severe O
or O
Fatal O
Adverse O
Reactions O
in O
Patients O
with O
Low O
or O
Absent O
Dihydropyrimidine O
Dehydrogenase O
( O
DPD O
) O
Activity O
: O
Withhold O
or O
permanently O
discontinue O
XELODA O
in O
patients O
with O
evidence O
of O
acute O
early-onset O
or O
unusually O
severe O
toxicity O
, O
which O
may O
indicate O
near O
complete O
or O
total O
absence O
of O
DPD O
activity O
. O

No O
XELODA O
dose O
has O
been O
proven O
safe O
in O
patients O
with O
absent O
DPD O
activity O
. O

( O
5.4 O
) O
* O
Dehydration O
and O
Renal O
Failure O
: O
Interrupt O
XELODA O
treatment O
until O
dehydration O
is O
corrected O
. O

Potential O
risk O
of O
acute O
renal O
failure O
secondary O
to O
dehydration O
. O

Monitor O
and O
correct O
dehydration O
. O

( O
5.5 O
) O
. O

* O
Embryo-Fetal O
Toxicity O
: O
Can O
cause O
fetal O
harm O
. O

Advise O
females O
of O
reproductive O
potential O
of O
the O
potential O
risk O
to O
a O
fetus O
and O
to O
use O
effective O
contraception O
. O

( O
5.6 O
, O
8.1 O
, O
8.3 O
) O
* O
Mucocutaneous O
and O
Dermatologic O
Toxicity O
: O
Severe O
mucocutaneous O
reactions O
, O
Steven-Johnson O
Syndrome O
( O
SJS O
) O
and O
Toxic O
Epidermal O
Necrolysis O
( O
TEN O
) O
, O
have O
been O
reported O
. O

XELODA O
should O
be O
permanently O
discontinued O
in O
patients O
who O
experience O
a O
severe O
mucocutaneous O
reaction O
during O
treatment O
. O

XELODA O
may O
induce O
hand-and-foot O
syndrome O
. O

Persistent O
or O
severe O
hand-and-foot O
syndrome O
can O
lead O
to O
loss O
of O
fingerprints O
which O
could O
impact O
patient O
identification O
. O

Interrupt O
XELODA O
treatment O
until O
the O
hand-and-foot O
syndrome O
event O
resolves O
or O
decreases O
in O
intensity O
. O

( O
5.7 O
) O
* O
Hyperbilirubinemia O
: O
Interrupt O
XELODA O
treatment O
immediately O
until O
the O
hyperbilirubinemia O
resolves O
or O
decreases O
in O
intensity O
. O

( O
5.8 O
) O
* O
Hematologic O
: O
Do O
not O
treat O
patients O
with O
neutrophil O
counts O
< O
1.5 O
* O
10 O
9 O
/L O
or O
thrombocyte O
counts O
< O
100 O
* O
10 O
9 O
/L O
. O

If O
grade O
3-4 O
neutropenia O
or O
thrombocytopenia O
occurs O
, O
stop O
therapy O
until O
condition O
resolves O
. O

( O
5.9 O
) O
5.1 O
Coagulopathy B-NonOSE_AE
Patients O
receiving O
concomitant O
capecitabine O
and O
oral O
coumarin-derivative O
anticoagulant O
therapy O
should O
have O
their O
anticoagulant O
response O
( O
INR O
or O
prothrombin O
time O
) O
monitored O
closely O
with O
great O
frequency O
and O
the O
anticoagulant O
dose O
should O
be O
adjusted O
accordingly O
[ O
see O
Boxed O
Warning O
and O
Drug O
Interactions O
( O
7.1 O
) O
] O
. O

5.2 O
Diarrhea O
XELODA O
can O
induce O
diarrhea B-OSE_Labeled_AE
, O
sometimes O
severe O
. O

Patients O
with O
severe O
diarrhea B-NonOSE_AE
should O
be O
carefully O
monitored O
and O
given O
fluid O
and O
electrolyte O
replacement O
if O
they O
become O
dehydrated O
. O

In O
875 O
patients O
with O
either O
metastatic O
breast B-Not_AE_Candidate
or O
colorectal O
cancer I-Not_AE_Candidate
who O
received O
XELODA O
monotherapy O
, O
the O
median O
time O
to O
first O
occurrence O
of O
grade O
2 O
to O
4 O
diarrhea B-OSE_Labeled_AE
was O
34 O
days O
( O
range O
from O
1 O
to O
369 O
days O
) O
. O

The O
median O
duration O
of O
grade O
3 O
to O
4 O
diarrhea B-OSE_Labeled_AE
was O
5 O
days O
. O

National O
Cancer O
Institute O
of O
Canada O
( O
NCIC O
) O
grade O
2 O
diarrhea B-NonOSE_AE
is O
defined O
as O
an O
increase B-NonOSE_AE
of I-NonOSE_AE
4 I-NonOSE_AE
to I-NonOSE_AE
6 I-NonOSE_AE
stools I-NonOSE_AE
/ I-NonOSE_AE
day I-NonOSE_AE
or I-NonOSE_AE
nocturnal I-NonOSE_AE
stools I-NonOSE_AE
, O
grade O
3 O
diarrhea B-NonOSE_AE
as O
an O
increase B-NonOSE_AE
of I-NonOSE_AE
7 I-NonOSE_AE
to I-NonOSE_AE
9 I-NonOSE_AE
stools I-NonOSE_AE
/ I-NonOSE_AE
day I-NonOSE_AE
or O
incontinence B-NonOSE_AE
and O
malabsorption B-NonOSE_AE
, O
and O
grade O
4 O
diarrhea B-NonOSE_AE
as O
an O
increase B-NonOSE_AE
of I-NonOSE_AE
> I-NonOSE_AE
= I-NonOSE_AE
1 I-NonOSE_AE
0 I-NonOSE_AE
stools I-NonOSE_AE
/ I-NonOSE_AE
day I-NonOSE_AE
or O
grossly B-NonOSE_AE
bloody I-NonOSE_AE
diarrhea I-NonOSE_AE
or O
the O
need O
for O
parenteral O
support O
. O

If O
grade O
2 O
, O
3 O
or O
4 O
diarrhea B-NonOSE_AE
occurs O
, O
administration O
of O
XELODA O
should O
be O
immediately O
interrupted O
until O
the O
diarrhea B-NonOSE_AE
resolves O
or O
decreases O
in O
intensity O
to O
grade O
1 O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

Standard O
antidiarrheal O
treatments O
( O
e.g. O
, O
loperamide O
) O
are O
recommended O
. O

Necrotizing B-OSE_Labeled_AE
enterocolitis I-OSE_Labeled_AE
( O
typhlitis B-OSE_Labeled_AE
) O
has O
been O
reported O
. O

5.3 O
Cardiotoxicity O
The O
cardiotoxicity B-OSE_Labeled_AE
observed O
with O
XELODA O
includes O
myocardial B-OSE_Labeled_AE
infarction/ O
ischemia I-OSE_Labeled_AE
, O
angina B-OSE_Labeled_AE
, O
dysrhythmias B-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
arrest I-OSE_Labeled_AE
, O
cardiac B-OSE_Labeled_AE
failure I-OSE_Labeled_AE
, O
sudden B-OSE_Labeled_AE
death I-OSE_Labeled_AE
, O
electrocardiographic B-OSE_Labeled_AE
changes I-OSE_Labeled_AE
, O
and O
cardiomyopathy B-OSE_Labeled_AE
. O

These O
adverse O
reactions O
may O
be O
more O
common O
in O
patients O
with O
a O
prior O
history O
of O
coronary B-Not_AE_Candidate
artery I-Not_AE_Candidate
disease I-Not_AE_Candidate
. O

5.4 O
Dihydropyrimidine O
Dehydrogenase O
Deficiency O
Based O
on O
postmarketing O
reports O
, O
patients O
with O
certain O
homozygous O
or O
certain O
compound O
heterozygous O
mutations O
in O
the O
DPD O
gene O
that O
result O
in O
complete O
or O
near O
complete O
absence B-Not_AE_Candidate
of I-Not_AE_Candidate
DPD I-Not_AE_Candidate
activity I-Not_AE_Candidate
are O
at O
increased O
risk O
for O
acute O
early-onset O
of O
toxicity O
and O
severe O
, O
life-threatening O
, O
or O
fatal B-NonOSE_AE
adverse O
reactions O
caused O
by O
XELODA O
( O
e.g. O
, O
mucositis B-OSE_Labeled_AE
, O
diarrhea B-OSE_Labeled_AE
, O
neutropenia B-OSE_Labeled_AE
, O
and O
neurotoxicity B-OSE_Labeled_AE
) O
. O

Patients O
with O
partial O
DPD O
activity O
may O
also O
have O
increased O
risk O
of O
severe O
, O
life-threatening O
, O
or O
fatal B-NonOSE_AE
adverse O
reactions O
caused O
by O
XELODA O
. O

Withhold O
or O
permanently O
discontinue O
XELODA O
based O
on O
clinical O
assessment O
of O
the O
onset O
, O
duration O
and O
severity O
of O
the O
observed O
toxicities O
in O
patients O
with O
evidence O
of O
acute O
early-onset O
or O
unusually O
severe O
toxicity O
, O
which O
may O
indicate O
near O
complete O
or O
total O
absence O
of O
DPD O
activity O
. O

No O
XELODA O
dose O
has O
been O
proven O
safe O
for O
patients O
with O
complete O
absence O
of O
DPD O
activity O
. O

There O
is O
insufficient O
data O
to O
recommend O
a O
specific O
dose O
in O
patients O
with O
partial O
DPD O
activity O
as O
measured O
by O
any O
specific O
test O
. O

5.5 O
Dehydration O
and O
Renal O
Failure O
Dehydration B-OSE_Labeled_AE
has O
been O
observed O
and O
may O
cause O
acute B-NonOSE_AE
renal I-NonOSE_AE
failure I-NonOSE_AE
which O
can O
be O
fatal B-NonOSE_AE
. O

Patients O
with O
pre-existing O
compromised B-Not_AE_Candidate
renal I-Not_AE_Candidate
function I-Not_AE_Candidate
or O
who O
are O
receiving O
concomitant O
XELODA O
with O
known O
nephrotoxic B-NonOSE_AE
agents I-NonOSE_AE
are O
at O
higher O
risk O
. O

Patients O
with O
anorexia B-Not_AE_Candidate
, O
asthenia B-Not_AE_Candidate
, O
nausea B-Not_AE_Candidate
, O
vomiting B-Not_AE_Candidate
or O
diarrhea B-Not_AE_Candidate
may O
rapidly O
become O
dehydrated B-NonOSE_AE
. O

Monitor O
patients O
when O
XELODA O
is O
administered O
to O
prevent O
and O
correct O
dehydration B-NonOSE_AE
at O
the O
onset O
. O

If O
grade O
2 O
( O
or O
higher O
) O
dehydration B-NonOSE_AE
occurs O
, O
XELODA O
treatment O
should O
be O
immediately O
interrupted O
and O
the O
dehydration B-NonOSE_AE
corrected O
. O

Treatment O
should O
not O
be O
restarted O
until O
the O
patient O
is O
rehydrated O
and O
any O
precipitating O
causes O
have O
been O
corrected O
or O
controlled O
. O

Dose O
modifications O
should O
be O
applied O
for O
the O
precipitating O
adverse O
event O
as O
necessary O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

Patients O
with O
moderate O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
at O
baseline O
require O
dose O
reduction O
[ O
see O
Dosage O
and O
Administration O
( O
2.4 O
) O
] O
. O

Patients O
with O
mild O
and O
moderate O
renal B-Not_AE_Candidate
impairment I-Not_AE_Candidate
at O
baseline O
should O
be O
carefully O
monitored O
for O
adverse O
reactions O
. O

Prompt O
interruption O
of O
therapy O
with O
subsequent O
dose O
adjustments O
is O
recommended O
if O
a O
patient O
develops O
a O
grade O
2 O
to O
4 O
adverse O
event O
as O
outlined O
in O
Table O
2 O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
, O
Use O
in O
Specific O
Populations O
( O
8.7 O
) O
, O
and O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

5.6 O
Embryo B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Fetal I-OSE_Labeled_AE
Toxicity I-OSE_Labeled_AE
Based O
on O
findings O
from O
animal O
reproduction O
studies O
and O
its O
mechanism O
of O
action O
, O
XELODA O
may O
cause O
fetal B-OSE_Labeled_AE
harm I-OSE_Labeled_AE
when O
given O
to O
a O
pregnant B-Not_AE_Candidate
woman O
[ O
see O
Clinical O
Pharmacology O
( O
12.1 O
) O
] O
. O

Limited O
available O
data O
are O
not O
sufficient O
to O
inform O
use O
of O
XELODA O
in O
pregnant B-Not_AE_Candidate
women O
. O

In O
animal O
reproduction O
studies O
, O
administration O
of O
capecitabine O
to O
pregnant B-NonOSE_AE
animals O
during O
the O
period O
of O
organogenesis O
caused O
embryolethality B-NonOSE_AE
and O
teratogenicity B-NonOSE_AE
in O
mice O
and O
embryolethality B-NonOSE_AE
in O
monkeys O
at O
0.2 O
and O
0.6 O
times O
the O
exposure O
( O
AUC O
) O
in O
patients O
receiving O
the O
recommended O
dose O
respectively O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.1 O
) O
] O
. O

Apprise O
pregnant B-Not_AE_Candidate
women O
of O
the O
potential O
risk B-OSE_Labeled_AE
to I-OSE_Labeled_AE
a I-OSE_Labeled_AE
fetus I-OSE_Labeled_AE
. O

Advise O
females O
of O
reproductive O
potential O
to O
use O
effective O
contraception O
during O
treatment O
and O
for O
6 O
months O
following O
the O
last O
dose O
of O
XELODA O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.3 O
) O
] O
. O

5.7 O
Mucocutaneous B-OSE_Labeled_AE
and O
Dermatologic O
Toxicity I-OSE_Labeled_AE
Severe O
mucocutaneous B-OSE_Labeled_AE
reactions I-OSE_Labeled_AE
, O
some O
with O
fatal B-NonOSE_AE
outcome O
, O
such O
as O
Stevens B-OSE_Labeled_AE
- I-OSE_Labeled_AE
Johnson I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
and O
Toxic B-OSE_Labeled_AE
Epidermal I-OSE_Labeled_AE
Necrolysis I-OSE_Labeled_AE
( I-OSE_Labeled_AE
TEN I-OSE_Labeled_AE
) O
can O
occur O
in O
patients O
treated O
with O
XELODA O
[ O
see O
Adverse O
Reactions O
( O
6.4 O
) O
] O
. O

XELODA O
should O
be O
permanently O
discontinued O
in O
patients O
who O
experience O
a O
severe O
mucocutaneous B-NonOSE_AE
reaction I-NonOSE_AE
possibly O
attributable O
to O
XELODA O
treatment O
. O

Hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
and I-OSE_Labeled_AE
- I-OSE_Labeled_AE
foot I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
( O
palmar B-OSE_Labeled_AE
- I-OSE_Labeled_AE
plantar I-OSE_Labeled_AE
erythrodysesthesia I-OSE_Labeled_AE
or O
chemotherapy B-OSE_Labeled_AE
- I-OSE_Labeled_AE
induced I-OSE_Labeled_AE
acral I-OSE_Labeled_AE
erythema I-OSE_Labeled_AE
) O
is O
a O
cutaneous B-OSE_Labeled_AE
toxicity I-OSE_Labeled_AE
. O

Median O
time O
to O
onset O
was O
79 O
days O
( O
range O
from O
11 O
to O
360 O
days O
) O
with O
a O
severity O
range O
of O
grades O
1 O
to O
3 O
for O
patients O
receiving O
XELODA O
monotherapy O
in O
the O
metastatic O
setting O
. O

Grade O
1 O
is O
characterized O
by O
any O
of O
the O
following O
: O
numbness B-NonOSE_AE
, O
dysesthesia B-NonOSE_AE
/ O
paresthesia B-NonOSE_AE
, O
tingling B-NonOSE_AE
, O
painless B-NonOSE_AE
swelling I-NonOSE_AE
or O
erythema O
of I-NonOSE_AE
the I-NonOSE_AE
hands I-NonOSE_AE
and/or O
feet O
and/or O
discomfort O
which O
does O
not O
disrupt O
normal O
activities O
. O

Grade O
2 O
hand B-NonOSE_AE
- I-NonOSE_AE
and I-NonOSE_AE
- I-NonOSE_AE
foot I-NonOSE_AE
syndrome I-NonOSE_AE
is O
defined O
as O
painful B-NonOSE_AE
erythema I-NonOSE_AE
and O
swelling O
of I-NonOSE_AE
the I-NonOSE_AE
hands I-NonOSE_AE
and/or O
feet O
and/or O
discomfort O
affecting O
the O
patient O
's O
activities O
of O
daily O
living O
. O

Grade O
3 O
hand B-NonOSE_AE
- I-NonOSE_AE
and I-NonOSE_AE
- I-NonOSE_AE
foot I-NonOSE_AE
syndrome I-NonOSE_AE
is O
defined O
as O
moist B-NonOSE_AE
desquamation I-NonOSE_AE
, O
ulceration O
, O
blistering O
or O
severe O
pain O
of O
the O
hands I-NonOSE_AE
and/or O
feet O
and/or O
severe O
discomfort O
that O
causes O
the O
patient O
to O
be O
unable B-NonOSE_AE
to I-NonOSE_AE
work I-NonOSE_AE
or I-NonOSE_AE
perform I-NonOSE_AE
activities I-NonOSE_AE
of I-NonOSE_AE
daily I-NonOSE_AE
living I-NonOSE_AE
. O

Persistent O
or O
severe O
hand B-NonOSE_AE
- I-NonOSE_AE
and I-NonOSE_AE
- I-NonOSE_AE
foot I-NonOSE_AE
syndrome I-NonOSE_AE
( O
grade O
2 O
and O
above O
) O
can O
eventually O
lead O
to O
loss B-NonOSE_AE
of I-NonOSE_AE
fingerprints I-NonOSE_AE
which O
could O
impact O
patient O
identification O
. O

If O
grade O
2 O
or O
3 O
hand B-NonOSE_AE
- I-NonOSE_AE
and I-NonOSE_AE
- I-NonOSE_AE
foot I-NonOSE_AE
syndrome I-NonOSE_AE
occurs O
, O
administration O
of O
XELODA O
should O
be O
interrupted O
until O
the O
event O
resolves O
or O
decreases O
in O
intensity O
to O
grade O
1 O
. O

Following O
grade O
3 O
hand B-NonOSE_AE
- I-NonOSE_AE
and I-NonOSE_AE
- I-NonOSE_AE
foot I-NonOSE_AE
syndrome I-NonOSE_AE
, O
subsequent O
doses O
of O
XELODA O
should O
be O
decreased O
[ O
see O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.8 O
Hyperbilirubinemia O
In O
875 O
patients O
with O
either O
metastatic O
breast B-Not_AE_Candidate
or O
colorectal O
cancer I-Not_AE_Candidate
who O
received O
at O
least O
one O
dose O
of O
XELODA O
1250 O
mg/m O
2 O
twice O
daily O
as O
monotherapy O
for O
2 O
weeks O
followed O
by O
a O
1-week O
rest O
period O
, O
grade O
3 O
( O
1.5-3 O
* O
ULN O
) O
hyperbilirubinemia B-OSE_Labeled_AE
occurred O
in O
15.2 O
% O
( O
n=133 O
) O
of O
patients O
and O
grade O
4 O
( O
> O
3 O
* O
ULN O
) O
hyperbilirubinemia B-OSE_Labeled_AE
occurred O
in O
3.9 O
% O
( O
n=34 O
) O
of O
patients O
. O

Of O
566 O
patients O
who O
had O
hepatic B-Not_AE_Candidate
metastases I-Not_AE_Candidate
at O
baseline O
and O
309 O
patients O
without O
hepatic B-NonOSE_AE
metastases I-NonOSE_AE
at O
baseline O
, O
grade O
3 O
or O
4 O
hyperbilirubinemia B-OSE_Labeled_AE
occurred O
in O
22.8 O
% O
and O
12.3 O
% O
, O
respectively O
. O

Of O
the O
167 O
patients O
with O
grade O
3 O
or O
4 O
hyperbilirubinemia B-OSE_Labeled_AE
, O
18.6 O
% O
( O
n=31 O
) O
also O
had O
postbaseline O
elevations B-OSE_Labeled_AE
( O
grades O
1 O
to O
4 O
, O
without O
elevations O
at O
baseline O
) O
in O
alkaline I-OSE_Labeled_AE
phosphatase I-OSE_Labeled_AE
and O
27.5 O
% O
( O
n=46 O
) O
had O
postbaseline O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
transaminases I-OSE_Labeled_AE
at O
any O
time O
( O
not O
necessarily O
concurrent O
) O
. O

The O
majority O
of O
these O
patients O
, O
64.5 O
% O
( O
n=20 O
) O
and O
71.7 O
% O
( O
n=33 O
) O
, O
had O
liver B-Not_AE_Candidate
metastases I-Not_AE_Candidate
at O
baseline O
. O

In O
addition O
, O
57.5 O
% O
( O
n=96 O
) O
and O
35.3 O
% O
( O
n=59 O
) O
of O
the O
167 O
patients O
had O
elevations B-OSE_Labeled_AE
( O
grades O
1 O
to O
4 O
) O
at O
both O
prebaseline O
and O
postbaseline O
in O
alkaline O
phosphatase O
or O
transaminases I-OSE_Labeled_AE
, O
respectively O
. O

Only O
7.8 O
% O
( O
n=13 O
) O
and O
3.0 O
% O
( O
n=5 O
) O
had O
grade O
3 O
or O
4 O
elevations B-OSE_Labeled_AE
in I-OSE_Labeled_AE
alkaline O
phosphatase O
or O
transaminases I-OSE_Labeled_AE
. O

In O
the O
596 O
patients O
treated O
with O
XELODA O
as O
first-line O
therapy O
for O
metastatic O
colorectal B-Not_AE_Candidate
cancer I-Not_AE_Candidate
, O
the O
incidence O
of O
grade O
3 O
or O
4 O
hyperbilirubinemia B-OSE_Labeled_AE
was O
similar O
to O
the O
overall O
clinical O
trial O
safety O
database O
of O
XELODA O
monotherapy O
. O

The O
median O
time O
to O
onset O
for O
grade O
3 O
or O
4 O
hyperbilirubinemia B-OSE_Labeled_AE
in O
the O
colorectal B-Not_AE_Candidate
cancer I-Not_AE_Candidate
population O
was O
64 O
days O
and O
median O
total B-OSE_Labeled_AE
bilirubin I-OSE_Labeled_AE
increased I-OSE_Labeled_AE
from O
8 O
um/L O
at O
baseline O
to O
13 O
um/L O
during O
treatment O
with O
XELODA O
. O

Of O
the O
136 O
colorectal B-Not_AE_Candidate
cancer I-Not_AE_Candidate
patients O
with O
grade O
3 O
or O
4 O
hyperbilirubinemia B-OSE_Labeled_AE
, O
49 O
patients O
had O
grade O
3 O
or O
4 O
hyperbilirubinemia B-OSE_Labeled_AE
as O
their O
last O
measured O
value O
, O
of O
which O
46 O
had O
liver B-Not_AE_Candidate
metastases I-Not_AE_Candidate
at O
baseline O
. O

In O
251 O
patients O
with O
metastatic O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
who O
received O
a O
combination O
of O
XELODA O
and O
docetaxel O
, O
grade O
3 O
( O
1.5 O
to O
3 O
* O
ULN O
) O
hyperbilirubinemia B-OSE_Labeled_AE
occurred O
in O
7 O
% O
( O
n=17 O
) O
and O
grade O
4 O
( O
> O
3 O
* O
ULN O
) O
hyperbilirubinemia B-OSE_Labeled_AE
occurred O
in O
2 O
% O
( O
n=5 O
) O
. O

If O
drug-related O
grade O
3 O
to O
4 O
elevations B-NonOSE_AE
in I-NonOSE_AE
bilirubin I-NonOSE_AE
occur O
, O
administration O
of O
XELODA O
should O
be O
immediately O
interrupted O
until O
the O
hyperbilirubinemia B-NonOSE_AE
decreases I-NonOSE_AE
to O
< O
=3.0 O
* O
ULN O
[ O
see O
recommended O
dose O
modifications O
under O
Dosage O
and O
Administration O
( O
2.3 O
) O
] O
. O

5.9 O
Hematologic O
In O
875 O
patients O
with O
either O
metastatic O
breast B-Not_AE_Candidate
or O
colorectal O
cancer I-Not_AE_Candidate
who O
received O
a O
dose O
of O
1250 O
mg/m O
2 O
administered O
twice O
daily O
as O
monotherapy O
for O
2 O
weeks O
followed O
by O
a O
1-week O
rest O
period O
, O
3.2 O
% O
, O
1.7 O
% O
, O
and O
2.4 O
% O
of O
patients O
had O
grade O
3 O
or O
4 O
neutropenia B-OSE_Labeled_AE
, O
thrombocytopenia B-OSE_Labeled_AE
or O
decreases B-OSE_Labeled_AE
in I-OSE_Labeled_AE
hemoglobin I-OSE_Labeled_AE
, O
respectively O
. O

In O
251 O
patients O
with O
metastatic O
breast B-Not_AE_Candidate
cancer I-Not_AE_Candidate
who O
received O
a O
dose O
of O
XELODA O
in O
combination O
with O
docetaxel O
, O
68 O
% O
had O
grade O
3 O
or O
4 O
neutropenia B-OSE_Labeled_AE
, O
2.8 O
% O
had O
grade O
3 O
or O
4 O
thrombocytopenia B-OSE_Labeled_AE
, O
and O
9.6 O
% O
had O
grade O
3 O
or O
4 O
anemia B-OSE_Labeled_AE
. O

Patients O
with O
baseline O
neutrophil B-Not_AE_Candidate
counts I-Not_AE_Candidate
of I-Not_AE_Candidate
< I-Not_AE_Candidate
1 I-Not_AE_Candidate
. I-Not_AE_Candidate
5 I-Not_AE_Candidate
* I-Not_AE_Candidate
1 I-Not_AE_Candidate
0 I-Not_AE_Candidate
9 I-Not_AE_Candidate
/ I-Not_AE_Candidate
L I-Not_AE_Candidate
and/or O
thrombocyte B-Not_AE_Candidate
counts I-Not_AE_Candidate
of I-Not_AE_Candidate
< I-Not_AE_Candidate
1 I-Not_AE_Candidate
0 I-Not_AE_Candidate
0 I-Not_AE_Candidate
* I-Not_AE_Candidate
1 I-Not_AE_Candidate
0 I-Not_AE_Candidate
9 I-Not_AE_Candidate
/ I-Not_AE_Candidate
L I-Not_AE_Candidate
should O
not O
be O
treated O
with O
XELODA O
. O

If O
unscheduled O
laboratory O
assessments O
during O
a O
treatment O
cycle O
show O
grade O
3 O
or O
4 O
hematologic B-NonOSE_AE
toxicity I-NonOSE_AE
, O
treatment O
with O
XELODA O
should O
be O
interrupted O
. O

5.10 O
Geriatric O
Patients O
Patients O
> O
=80 O
years O
old O
may O
experience O
a O
greater O
incidence O
of O
grade O
3 O
or O
4 O
adverse O
reactions O
. O

In O
875 O
patients O
with O
either O
metastatic O
breast B-Not_AE_Candidate
or O
colorectal O
cancer I-Not_AE_Candidate
who O
received O
XELODA O
monotherapy O
, O
62 O
% O
of O
the O
21 O
patients O
> O
=80 O
years O
of O
age O
treated O
with O
XELODA O
experienced O
a O
treatment-related O
grade O
3 O
or O
4 O
adverse O
event O
: O
diarrhea B-OSE_Labeled_AE
in O
6 O
( O
28.6 O
% O
) O
, O
nausea B-OSE_Labeled_AE
in O
3 O
( O
14.3 O
% O
) O
, O
hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
and I-OSE_Labeled_AE
- I-OSE_Labeled_AE
foot I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
in O
3 O
( O
14.3 O
% O
) O
, O
and O
vomiting B-OSE_Labeled_AE
in O
2 O
( O
9.5 O
% O
) O
patients O
. O

Among O
the O
10 O
patients O
70 O
years O
of O
age O
and O
greater O
( O
no O
patients O
were O
> O
80 O
years O
of O
age O
) O
treated O
with O
XELODA O
in O
combination O
with O
docetaxel O
, O
30 O
% O
( O
3 O
out O
of O
10 O
) O
of O
patients O
experienced O
grade O
3 O
or O
4 O
diarrhea B-OSE_Labeled_AE
and O
stomatitis B-OSE_Labeled_AE
, O
and O
40 O
% O
( O
4 O
out O
of O
10 O
) O
experienced O
grade O
3 O
hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
and I-OSE_Labeled_AE
- I-OSE_Labeled_AE
foot I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
. O

Among O
the O
67 O
patients O
> O
=60 O
years O
of O
age O
receiving O
XELODA O
in O
combination O
with O
docetaxel O
, O
the O
incidence O
of O
grade O
3 O
or O
4 O
treatment-related O
adverse O
reactions O
, O
treatment-related O
serious O
adverse O
reactions O
, O
withdrawals O
due O
to O
adverse O
reactions O
, O
treatment O
discontinuations O
due O
to O
adverse O
reactions O
and O
treatment O
discontinuations O
within O
the O
first O
two O
treatment O
cycles O
was O
higher O
than O
in O
the O
< O
60 O
years O
of O
age O
patient O
group O
. O

In O
995 O
patients O
receiving O
XELODA O
as O
adjuvant O
therapy O
for O
Dukes B-Not_AE_Candidate
' I-Not_AE_Candidate
C I-Not_AE_Candidate
colon I-Not_AE_Candidate
cancer I-Not_AE_Candidate
after O
resection B-Not_AE_Candidate
of I-Not_AE_Candidate
the I-Not_AE_Candidate
primary I-Not_AE_Candidate
tumor I-Not_AE_Candidate
, O
41 O
% O
of O
the O
398 O
patients O
> O
=65 O
years O
of O
age O
treated O
with O
XELODA O
experienced O
a O
treatment-related O
grade O
3 O
or O
4 O
adverse O
event O
: O
hand B-OSE_Labeled_AE
- I-OSE_Labeled_AE
and I-OSE_Labeled_AE
- I-OSE_Labeled_AE
foot I-OSE_Labeled_AE
syndrome I-OSE_Labeled_AE
in O
75 O
( O
18.8 O
% O
) O
, O
diarrhea B-OSE_Labeled_AE
in O
52 O
( O
13.1 O
% O
) O
, O
stomatitis B-OSE_Labeled_AE
in O
12 O
( O
3.0 O
% O
) O
, O
neutropenia B-OSE_Labeled_AE
/ O
granulocytopenia B-OSE_Labeled_AE
in O
11 O
( O
2.8 O
% O
) O
, O
vomiting B-OSE_Labeled_AE
in O
6 O
( O
1.5 O
% O
) O
, O
and O
nausea B-OSE_Labeled_AE
in O
5 O
( O
1.3 O
% O
) O
patients O
. O

In O
patients O
> O
=65 O
years O
of O
age O
( O
all O
randomized O
population O
; O
capecitabine O
188 O
patients O
, O
5-FU/LV O
208 O
patients O
) O
treated O
for O
Dukes B-Not_AE_Candidate
' I-Not_AE_Candidate
C I-Not_AE_Candidate
colon I-Not_AE_Candidate
cancer I-Not_AE_Candidate
after O
resection B-Not_AE_Candidate
of I-Not_AE_Candidate
the I-Not_AE_Candidate
primary I-Not_AE_Candidate
tumor I-Not_AE_Candidate
, O
the O
hazard O
ratios O
for O
disease-free O
survival O
and O
overall O
survival O
for O
XELODA O
compared O
to O
5-FU/LV O
were O
1.01 O
( O
95 O
% O
C.I O
. O

0.80 O
- O
1.27 O
) O
and O
1.04 O
( O
95 O
% O
C.I O
. O

0.79 O
- O
1.37 O
) O
, O
respectively O
. O

5.11 O
Hepatic O
Insufficiency O
Patients O
with O
mild O
to O
moderate O
hepatic B-Not_AE_Candidate
dysfunction I-Not_AE_Candidate
due O
to O
liver B-Not_AE_Candidate
metastases I-Not_AE_Candidate
should O
be O
carefully O
monitored O
when O
XELODA O
is O
administered O
. O

The O
effect O
of O
severe O
hepatic B-NonOSE_AE
dysfunction I-NonOSE_AE
on O
the O
disposition O
of O
XELODA O
is O
not O
known O
[ O
see O
Use O
in O
Specific O
Populations O
( O
8.6 O
) O
and O
Clinical O
Pharmacology O
( O
12.3 O
) O
] O
. O

5.12 O
Combination O
With O
Other O
Drugs O
Use O
of O
XELODA O
in O
combination O
with O
irinotecan O
has O
not O
been O
adequately O
studied O
. O

